Vilya | LinkedIn (original) (raw)

About us

Vilya is a cutting-edge computational biotechnology company, co-founded a team of scientists from from the Institute of Protein Design (IPD) led by David Baker, Ph.D. and by ARCH Venture Partners. At Vilya, we are creating a novel class of medicines to precisely target disease biology. Our platform is built on ground-breaking research in advanced computational approaches and taps into uncharted chemical space within cyclic peptides to design new molecular structures not found in nature. We aim to boldly leverage cutting edge computing to change how we design new medicines, and to ultimately cure diseases. Who will love working with us? We are a group of machine learning scientists, computational chemists, medicinal chemists, biologists and scientific enthusiasts that are driven to design and create life-altering medicines that will make a big impact on the world. Learn more about our job openings and join us! join@vilyatx.com

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

South San Francisco, CA

Type

Privately Held

Locations

Employees at Vilya

Updates

We’re excited to share that C&EN has listed Vilya as a Top 10 startup to watch! Sarah Braner highlights our work using modern structure prediction with high-throughput macrocycle synthesis to design de novo macrocyclic peptides. Our platform allows for the creation of diverse macrocycles, including those with noncanonical amino acids, offering a novel approach to drug discovery. Thank you to C&EN for featuring our efforts as we continue to explore new ways to tackle complex scientific problems and drive meaningful solutions for patients. Read more below ⬇️ to hear Cyrus Harmon and Inca Coman's perspectives on the success of Vilya and to learn why ARCH Venture Partners' Robert Nelsen decided to invest after just 5 minutes: https://lnkd.in/gtZcDz_7
Vilya designs new macrocyclic peptides cen.acs.org
Don’t miss the chance to meet and connect with our CEO Cyrus Harmon, Ph.D. at the EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain!
We are thrilled to celebrate the remarkable achievement of our scientific founder, Dr. David Baker, who has been awarded the 2024 #NobelPrize in #Chemistry for his pioneering work in computational protein design! 🏆🔬 Dr. Baker's groundbreaking research laid the foundation for a revolution in protein design, starting with the creation of a novel protein in 2003. His visionary work and ongoing achievements at the Baker Lab in the Institute for Protein Design, University of Washington has empowered a global community of researchers to push the boundaries of science, leading to the development of innovative proteins with applications in pharmaceuticals, vaccines, nanomaterials and beyond. At Vilya, we are proud to build upon this legacy by using advanced computational approaches to design novel, chemically diverse macrocycles to target disease biology with unprecedented precision. Vilya leaders Patrick Salveson, Ph.D., Chief Technology Officer, Adam Moyer, Ph.D., Director of Molecular Design and Nao Hiranuma, Ph.D., Director of Machine Learning Research were instrumental members of the Baker Lab and now scientific founders and leaders at Vilya. Our foundational work on macrocycle design, recently published in Science, expands on Dr. Baker’s discovery and exemplifies the innovative spirit that he instilled in all of us. As Adam shares, "David always finds a way to blend pragmatic development and visionary solutions in brilliant ways. And, more importantly, he relentlessly applies his effort to the grandest challenges he can identify. I am personally most grateful for the incredible lab environment that he fosters. He recognizes that the truly hard problems are best solved with deep collaboration between scientists that love their work." Join us in celebrating this monumental achievement and the bright future of medicine!✨#NobelPrize2024 #ComputationalBiotechnology #ProteinDesign #InnovationInMedicine #Macrocycles
Don’t miss the chance to meet and connect with our CEO at ESMO - European Society for Medical Oncology Congress 2024!
Excited to be attending the ESMO Congress 2024 in Spain! It’s inspiring to see the global community come together to share cutting-edge research and breakthroughs that will shape the future of cancer care. I'm grateful for the opportunity to connect with so many brilliant minds and discuss how we can continue advancing oncology research to improve patient outcomes. If you’re attending, I’d love to meet and explore opportunities for collaboration.
We are excited to welcome Anastasia Velentza, Ph.D., as the VP and Head of Biology at Vilya. Before joining Vilya, Anastasia led Discovery Technology at Plexium, a company focused on Targeted Protein Degradation. With over 20 years of experience in Drug Discovery, her expertise spans Discovery Biology and Molecular Pharmacology across various therapeutic areas. She has also held key positions at Novartis, Dart Neuroscience, and Ferring Pharmaceuticals. Anastasia is also the Founder of AVeNew Insights, a consulting business specializing in drug discovery. She earned her Ph.D. in Bioorganic Chemistry and a B.Sc. in Chemistry from the University of Patras, Greece. Her research has been recognized with numerous awards and is documented in over 25 publications, patents, and abstracts. Welcome to Vilya, Anastasia! #Leadership #Biotechnology #DrugDiscovery #Innovation
Earlier this summer, we had our second quarterly company-wide gathering that brought our Seattle and South SF teams together. We brainstormed a range of exciting new ideas to propel Vilya forward, leveraging the diverse expertise and perspectives within our teams. It's always inspiring to witness the dedication and creativity that each team member brings to the table. But we don't only talk science! We also enjoy good food, amazing colleagues, and even baseball games. Go, team Vilya! Here’s to continued collaboration, innovation, and the power of coming together as one team! #TeamVilya #Innovation #Collaboration
2,583 followers
5mo Edited
It's official! We're excited to announce the expansion of our Series A financing to $71 million from lead investor ARCH Venture Partners with participation from NVIDIA’s NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures. This milestone will accelerate the advancement of our proprietary computational drug design and development platform, and further our mission to create a new class of medicines that precisely target disease biology. We are also welcoming Greg Yap Partner at Menlo Ventures, to our board. Greg's insights and experience will be invaluable as we continue to innovate and grow. A big thank you to our incredible team and all our partners for making this possible. We are grateful for their support and confidence in our vision. Read more here: https://lnkd.in/gEuYP8rW #Vilya #BioTech #DrugDiscovery #Innovation
Check out Derek Lowe’s In the Pipeline commentary which underscores the foundational work of Vilya's computational macrocycle discovery platform, published in Science Magazine last month. His detailed analysis showcases how our innovative approach is advancing the prediction of non-natural peptide-like structures, pushing the boundaries of chemical probe and drug discovery. Dive into the full article to see how we're navigating this vast and promising chemical space!
Macrocycles from Thin Air science.org

Join now to see what you are missing